Login
Login     |     Register     |     Recover Username/Password

Liberum Management Change

Recommended Reading – Examining the Impact of SEC Guidance Changes on CEO Succession Planning, The Conference Board

May 19, 2010

Edward Ferris and Justin O’Brien recently published a paper for the Conference Board (members only) entitled, Examining the Impact of SEC Guidance Changes on CEO Succession Planning.  The paper is a must read for anyone interested in CEO succession and its implications for corporate governance and corporate performance.    According to the report as a result of the recent change by the SEC,

… regulators have reframed CEO succession as a risk management issue and placed its responsibility firmly in the boardroom. Succession planning responsibilities are redefined as “a key board function” and “a significant policy (and governance) issue … so that a company is not adversely affected by a vacancy in leadership.”

… the implications seem clear: boards will have to set more specific standards and requirements for CEO succession, take responsibility for results, and exercise discernable independence in the process.

Against this backdrop, the report seeks to answer three questions:

• What is the likely impact of this policy reversal?

• How will it practically affect the board?

• What should shareholders know about CEO succession plans, and why?

I highly recommend anyone interested in the succession issue read the paper.  If you are not a member of the Conference Board, you might want to contact one of the authors, Edward Ferris, at the Hedge Fund Solutions Research Center. His email is eferris@hedgerelations.com.


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now